incredible news story, incredible product, incredibly opportunity & mapp incredibly under-valued. Great to see independent people raving about levadex. I think this drug had blockbuster potential. dr says that 2/3rds of patients levadex works for. this means that out of 30 million people in usa around 20 million will likely love levadex. USA is 5% of global population so there could be some 100 million people worldwide who would love this drug. big pharma is likely drooling to own mapp. I think this stock is destined for $40 a share or so.